FDA Guidance: Post marketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application
Date: 2014-12-10
Source: fda.gov
Abstract:
This document provides guidance to industry on post marketing serious adverse event reporting for nonprescription (over-the-counter (OTC)) human drug products marketed without an approved application. In particular, this document gives guidance on (1) the minimum data elements that should be included in a serious adverse event report, (2) the label that should be included with the report, (3) reporting formats for paper and electronic submissions, and (4) how and where to submit the reports.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.
 |
Click here to download the file
|
|
